Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

The group is speaking with insurers, urging them to follow the science and hoping to give the companies “a neutral, ...

Belarus has freed Siarhei Tsikhanouski, a key dissident figure and the husband of exiled opposition leader Sviatlana ...

A listeria food poisoning outbreak that has killed three people and led to one pregnancy loss is linked to newly recalled ...

Novo Nordisk (NVO 1.20%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

Novo Nordisk stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.. As Reuters reports today, an online weight loss company called Noom has ...

Novo Nordisk's stock is still up more than 250% since Jørgensen took over as CEO in January 2017. But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024.

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.